Therapeutic monoclonal antibodies are surging in importance as approvals for antibody drugs proliferate. Alongside well-established biotherapeutics such as vaccines, other biologics including gene therapy vectors and siRNAs for gene silencing are continually being developed and biosimilar products are becoming a reality as early innovations in this field come off-patent.
We have been active in this field since its inception and have a well-developed practice relating to these innovative therapeutic products and their medical uses, production and delivery. Our Biotechnology and Life Sciences team has particular expertise with antibodies and is highly experienced in attacking and defending antibody patents in EPO Oppositions and Appeals. Clients ranging from major corporates to SMEs and universities engage us for patent drafting, filing and prosecution and freedom to operate matters and we also have experience in obtaining Supplementary Protection Certificates for biologics as well as for small molecule pharmaceuticals.